Results 221 to 230 of about 12,467 (245)

Ivacaftor

Reactions Weekly, 2014
openaire   +2 more sources

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

New England Journal of Medicine, 2019
Peter Gordon Middleton, Marcus A Mall, Larry C Lands   +2 more
exaly  

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine, 2020
Pierre-Régis Burgel, Phillipe Reix, Isabelle Sermet-Gaudelus   +2 more
exaly  

Ivacaftor

Reactions Weekly, 2017
openaire   +1 more source

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis

Science Translational Medicine, 2014
Charles R Esther, Nikolay V Dokholyan, Scott H Randell   +2 more
exaly  

Ivacaftor

Reactions Weekly, 2019
openaire   +1 more source

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Lancet Respiratory Medicine,the, 2018
Margaret Rosenfeld, Claire E Wainwright, Steve Cunningham   +2 more
exaly  

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

Lancet Respiratory Medicine,the, 2015
Richard Moss, Patrick A Flume, Susanna A Mccolley   +2 more
exaly  

Ivacaftor/lumacaftor

Reactions Weekly, 2018
  +4 more sources

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

American Journal of Respiratory and Critical Care Medicine, 2015
Gregory S Sawicki, Edward F Mckone, David J Pasta   +2 more
exaly